Ironwood Pharmaceuticals, Inc.(IRWD)

Description: Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. The company's lead product candidate, linaclotide, a guanylate cyclase type-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) gastrointestinal disorders under the LINZESS name in the United States and Constella name in the European Union. It also has a pipeline focused on the research and development of early development candidates and discovery research programs in various therapeutic areas, including gastrointestinal diseases, central nervous system disorders, allergic conditions, and cardiovascular diseases. Ironwood Pharmaceuticals has collaboration and license agreements with Forest Laboratories, Inc. to develop and commercialize linaclotide in North America; Almirall, S.A to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions; Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal conditions in Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and AstraZeneca AB to co-develop and co-commercialize linaclotide in China, including Hong Kong and Macau. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

---

Keywords: Cardiovascular Disease Therapeutic Products Peptides Macau Gastrointestinal Vascular Disease Gastroenterology Central Nervous System Disorders Constipation Irritable Bowel Syndrome Nervous System Disorders Gastrointestinal Disease Digestive Diseases Laxatives Almirall Gastrointestinal Disorders Linaclotide Chronic Idiopathic Constipation Functional Constipation Human Therapeutic Products

---

Home Page: www.ironwoodpharma.com

IRWD Technical Analysis

100 Summer Street
Boston, MA 02110
United States
Phone: 617 621 7722

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)